CD274 and neoplasm: Immune checkpoint blockade therapies targeting the programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) axis are now FDA-approved for treating a wide variety of tumours and are likely to be approved for additional indications in the near future [1].